Drugs / Glycovax-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05799651 | Apr 2023 → Jun 2024 overdue | COVID-19 | Glycovax Pharma Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycovax-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05799651 ↗ |
| Modality | Vaccine | “Glycovax-002, a Novel Vaccine Candidate Against COVID-19” NCT05799651 ↗ |